IN8bio (INAB) Stock Price, News & Analysis

Company Overview

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Key Stats

• Today's Range: $2.10 to $2.20
• 50-Day Range: $2.07 to $5.34
• 52-Week Range: $2.05 to $27.30
• Volume: 96,144 shs
• Average Volume: 102,169 shs
• Market Capitalization: $6.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $180.00
• Consensus Rating: Buy

IN8bio Stock Analysis - MarketRank™

IN8bio scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IN8bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IN8bio are expected to grow in the coming year, from ($0.56) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IN8bio is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IN8bio is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IN8bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.01% of the float of IN8bio has been sold short.

Short Interest Ratio / Days to Cover

IN8bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IN8bio has recently increased by 142.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IN8bio does not currently pay a dividend.

Dividend Growth

IN8bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.01% of the float of IN8bio has been sold short.

Short Interest Ratio / Days to Cover

IN8bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IN8bio has recently increased by 142.09%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 8 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

6 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IN8bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of IN8bio is held by insiders.

Percentage Held by Institutions

92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INAB Stock Analysis - Frequently Asked Questions

How have INAB shares performed this year?

IN8bio's stock was trading at $7.7160 at the beginning of the year. Since then, INAB shares have decreased by 72.8% and is now trading at $2.10.

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.80) by $0.30.

When did IN8bio's stock split?

IN8bio's stock reverse split on Friday, June 6th 2025.The 1-30 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did IN8bio IPO?

IN8bio (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IN8bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INAB
• CIK: 1740279
• Web: www.in8bio.com
• Phone: 646-600-6438
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $180.00
• High Stock Price Target: $180.00
• Low Stock Price Target: $180.00
• Potential Upside/Downside: +7,971.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($13.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -218.85%
• Return on Assets: -139.59%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 4.30
• Quick Ratio: 4.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.00 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 3,030,000
• Free Float: 2,739,000
• Market Cap: $6.76 million
• Optionable: Not Optionable
• Beta: N/A